Immune Design Corp (IMDZ) : Abingworth Llp added new position in Immune Design Corp during the most recent quarter end. The investment management firm now holds 197,300 shares of Immune Design Corp which is valued at $1,371,235 , the company said in a statement filed on Aug 12, 2016 with the SEC.Immune Design Corp makes up approximately 1.36% of Abingworth Llp’s portfolio.
Other Hedge Funds, Including , Vident Investment Advisory sold out all of its stake in IMDZ during the most recent quarter. The investment firm sold 73,608 shares of IMDZ which is valued $511,576.Tiaa Cref Investment Management boosted its stake in IMDZ in the latest quarter, The investment management firm added 6,812 additional shares and now holds a total of 43,523 shares of Immune Design Corp which is valued at $302,485.Blackrock Investment Management boosted its stake in IMDZ in the latest quarter, The investment management firm added 2,365 additional shares and now holds a total of 41,876 shares of Immune Design Corp which is valued at $291,038.Blackrock Institutional Trust Company N.a. reduced its stake in IMDZ by selling 1,340 shares or 0.58% in the most recent quarter. The Hedge Fund company now holds 229,546 shares of IMDZ which is valued at $1,595,345.
Immune Design Corp opened for trading at $6.9 and hit $6.98 on the upside on Monday, eventually ending the session at $6.86, with a gain of 0.15% or 0.01 points. The heightened volatility saw the trading volume jump to 73,991 shares. Company has a market cap of $138 M.
Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms ZVex and GLAAS which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action. The Company’s primary product candidates CMB305 and G100 utilize multiple immuno-oncology approaches and it believes address the shortcomings of existing therapies. The Company’s immuno-oncology product candidates are being developed in two separate approaches. The Specific Antigen approach uses selected antigens that are also present in the patient’s tumor. The Endogenous Antigen approach relies on endogenous tumor antigens released during tumor lysis by treatments such as chemotherapy or local radiation.